ClinPGx Blog (Page 48)

Sign in Subscribe

More issues

Mining the pharmacogenomics literature

Briefings in Bioinformatics Special Issue: Current Progress in Bioinformatics 2012 contains an editorial by Russ Altman discussing the current status of bioinformatics research. Among the articles in this special issue is a review on the current status of techniques for mining of the pharmacogenomics literature and includes descriptions of studies

New PGRN Featured Project and PI for the Month of August

The PGRN website is featuring a new project and investigator of the month from the PARC (Pharmacogenomics and Risk of Cardiovascular Disease) group.For detailed information, please visit the PGRN website.

Curators' Favorite Papers

Current Curators' Favorite Papers: The review by Alfirevic and Pirmohamed discusses genetic factors associated with drug-induced liver injury with a special focus on HLA gene variation [PMID: 22850601]. Parvez et al. reports that a common SNP on chromosome 4q25, which is associated with atrial fibrillation, modulates response to

A message about RFA-HG-12-016

RFA-HG-12-016 "Clinically relevant genetic variants resource: a unified approach for identifying genetic variants for clinical use (U01)." The PharmGKB team is excited to see this RFA because clinical genomics has great potential to impact medicine. PharmGKB catalogs genetic variation of relevance to drug response (pharmacogenomics)

New PGRN Featured Project and PI for the Month of July

The PGRN website is featuring a new project and investigator of the month from the PHAT (Pharmacogenetics of Asthma Treatment) group. For detailed information, please visit the PGRN website.

Effect of a genetic variant associated with Multiple Sclerosis mirrors response to anti-TNF therapy

Though anti-TNF therapy can be effective in the treatment of many auto-immune diseases including Rheumatoid Arthritis (RA), drugs that block TNF can promote or exacerbate Multiple Sclerosis (MS). A genetic variant (rs1800693) within the TNFRSF1A gene has been identified in multiple GWAS as being associated with MS but

New pathways on PharmGKB: Sorafenib PK and PD

We have added two new pathways: Sorafenib PK and PD pathways to our pathway collections. Sorafenib (Nexavar, BAY 43-9006) is a cancer drug used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma. It blocks tumor cell proliferation and angiogenesis by targeting various types of serine/threonine and

New Relationships File Available

PharmGKB has a new relationships file available for download. This file catalogs all the current relationships between drugs, genes, diseases, variants, and haplotypes in PharmGKB. These relationships are based on annotations generated by our curators. The new relationships file replaces and improves on the old relationships file. The entries in

PharmGKB has an opening for a scientific curator

PharmGKB is looking to fill a Curator position in the Department of Genetics at Stanford University. We are specifically looking for someone with a clinical or pharmacology background to add to the curation team. This position works with a group of curators to collect and analyze information from the scientific

Genetic contribution of response to opioids

Opioids are commonly prescribed for pain relief, yet many individuals suffer adverse side effects such as nausea, dizziness and sedation. A study published in this month's Anesthesiology set out to establish the relative contribution of genetic and environmental factors in opioid response. 114 monozygotic and dizygotic twin pairs